A carregar...
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
OBJECTIVES: Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carri...
Na minha lista:
| Publicado no: | Jpn J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7401714/ https://ncbi.nlm.nih.gov/pubmed/32328660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyaa042 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|